Seven Strategies for Avoiding a 483
Posted on Mon, Nov 07, 2011
In the fourth part of our series on FDA Inspections: Requirements, Procedures and Practices, upon the completion of the inspection, if the inspector will make observations of objectionable conditions these will be conveyed on a FORM FDA 483.
Click Icon to tell us what you think!
What a 483 is—and isn’t. After inspecting a food, drug, medical device, or biologic establishment, FDA prepares a written report of its inspection findings, following a debriefing. This report is intended primarily for internal FDA use and is not provided to the inspected institution at the conclusion of the on-site visit.
To provide the facility with its own written list of discrepancies noted during the inspection, FDA developed form FDA 483, “Notice of Inspectional Observations,” issued by the field investigator. Form 483 should contain only those observations that can be directly linked to a violation of regulations—not suggestions, guidance, or other comments. Although the 483 does not contain references to the regulations, each observation should be directly traceable to a section of the applicable regulations.
Items placed on a form 483 are the opinion of the FDA investigator on the scene, and may be subject to review by others within FDA. Current FDA policy requires that the agency write a follow-up letter to clinical investigators and IRBs. When the items on the 483 are confirmed in that letter, they may be taken as an official FDA position.
Conversely, there is no guarantee that the follow-up letter will be limited to the items listed on the 483, as additional review by FDA headquarters may identify significant regulatory violations that were not listed on the 483, which will be included in the follow-up letter.
Some investigators are willing to listen to the firm’s response to issues and at times may actually remove these findings from the FDA-483 document.The inspected facility can provide a written response to the observations in addition to discussing these during a conference with management. Generally, a report of the inspection and any management conference is prepared.
How does the District Office decide on further action?
A complete inspection report, including a Form 483 if issued, is then sent to the District Office. The District Office reviews the Establishment Inspection Report (EIR), as well as other information related to the site, and makes a decision on the inspection. The EIR and the content of the EIR often will determine whether the District Office will recommend an enforcement action to the appropriate Center.
When and how is the Center involved?
When the District Office makes a recommendation to a Center, the recommendation is supported by the FORM FDA 483, any response from facility management, the EIR, and any other items of evidence gathered during the inspection. The compliance in the Center will review the recommendation and either reject, accept, or request more information relating to the recommendation. If the recommendation for a Warning Letter is appropriate, then this is issued by the District Office for inspections or other reasons.
Who writes the Establishment Inspection Report and when can you obtain a copy?
After returning to the District Office, the inspector will write the EIR, which contains either positive or negative observations. All documentation of observed violations and all documents routinely collected are attached to the EIR. The district office evaluates the EIR and determines its classification. The headquarters, however, has the final authority to evaluate the EIR, so the EIR and all its attachments are forwarded to the appropriate headquarters office.
EIR classification refers to the FDA’s evaluation of whether the inspectional observations warrant agency action and whether such actions are supported by the documented evidence. The EIR classifications are:
- NAI: No major objectionable practices or situations were found
- VAI: Objectionable situations or practices were found, but the FDA is not prepared to take or recommend any official action
- OAI: Regulatory or administrative actions will be recommended.
The EIR will all of the documentation collected from site is sent to the FDA center that assigned the audit for review and comment. If company has sent a letter in response to the audit, it will also be included.
Does a good 483 response mean that no warning letter is forthcoming?
Yes, after headquarters make a classification, the Center informs the District Office and the investigator in writing of its determination. If the classification in NAI or VAI, the investigator is sent a letter stating that no violations were found or requesting voluntary corrections. An OAI classification generally requires a warning letter be issued to the investigators.
